Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease

Free Radical Research

Volumn 49, Issue 9, 2015, Pages 1129-1139

  Tripathy, D ^a   Chakraborty, J ^a   Mohanakumar, K P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Drug target; Infl ammatory mediators; Oxidative stress; Progressive neurodegeneration; Reactive oxygen species

Indexed keywords

NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; DOPAMINE; NEUROPROTECTIVE AGENT; NEUROTOXIN;

APOPTOSIS; BASAL GANGLION; BRAIN FUNCTION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GENETIC ASSOCIATION; GENETIC RISK; GLIOSIS; HUMAN; MEDIATOR RELEASE; MOLECULAR PATHOLOGY; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PLEIOTROPY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CELL PROLIFERATION; DEGENERATIVE DISEASE; INFLAMMATION; METABOLISM; MICROGLIA; MOUSE; NERVE DEGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; SUBSTANTIA NIGRA;

ANIMALIA; MUS;

ANIMALS; BASAL GANGLIA; BRAIN; CELL PROLIFERATION; DISEASE PROGRESSION; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; INFLAMMATION; MICE; MICROGLIA; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA;

EID: 84938651909     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2015.1045505     Document Type: Review

References (130)

1. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson ' s disease. Annu Rev Neurosci 2005;28:57-87.
2. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998;44:S72-84.
3. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53:S26-S38.
4. Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinfl am-matory mechanisms in Parkinson ' s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007;208:1-25.
5. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infi ltration of CD4 + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009 ; 119 : 182-192.
6. Pilleri M, Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson ' s disease. Expert Opin Drug Saf 2015;14:281-294.
7. Broadstock M, Ballard C, Corbett A. Latest treatment options for Alzheimer ' s disease, Parkinson ' s disease dementia and dementia with Lewy bodies. Expert Opin Pharmacother 2014;15:1797-1810.
8. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson ' s disease than women? J Neurol Neurosurg Psychiatry 2004;75:637-639.
9. Caroline MT, Melanie B, Ray ED. Parkinson Disease: A Global View. XIX,2. Parkinson Report. http://www.par-kinson.org/NationalParkinsonFoundation/fi les/da/da332eb3-ecaa-464f-adfb-b61a80851160.pdf>. Last Accessed 2008.
10. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson ' s disease. Mov Disord 1998;13:221-227.
11. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007;150: 963-976.
12. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009;27: 119-145.
13. Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML, Poderoso JJ. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson ' s disease. Nitric Oxide 2000;4:534-539.
14. Duncan AJ, Heales SJ. Nitric oxide and neurological disorders. Mol Aspects Med 2005;26:67-96.
15. Zhang L, Dawson VL, Dawson TM. Role of nitric oxide in Parkinson's disease. Pharmacol Ther 2006;109:33-41.
16. Singh S, Dikshit M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res Rev 2007 ; 54:233-250.
17. Li X, Ye X, Sun X, Liang Q, Tao L, Kang X, Chen J. Salidro-side protects against MPP(+)-induced apoptosis in PC12 cells by inhibiting the NO pathway. Brain Res 2011;1382:9-18.
18. Hirsch EC, Hunot S, Hartmann A. Neuroinfl ammatory processes in Parkinson ' s disease. Parkinsonism Relat Disord 2005;11 Suppl 1:S9-S15.
19. Hirsch EC, Vyas S, Hunot S. NeuroInflammation in Parkinson's disease. Parkinsonism Relat Disord 2012;18 Suppl 1:S210-212.
20. Rezai-Zadeh K, Gate D, Town T. CNS infi ltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 2009;4:462-475.
21. Mohanakumar KP, Hanbauer I, Chiueh CC. Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity. J Chem Neuroanat 1998;14:195-205.
22. Mohanakumar KP, Steinbusch HW. Hydroxyl radicals and nitric oxide in neurotoxicity and neuroprotection. J Chem Neuroanat 1998;14:125-127.
23. Rauhala P, Khaldi A, Mohanakumar KP, Chiueh CC. Apparent role of hydroxyl radicals in oxidative brain injury induced by sodium nitroprusside. Free Radic Biol Med 1998 ; 24 : 1065-1073.
24. Rauhala P, Mohanakumar KP, Sziraki I, Lin AM, Chiueh CC. S-nitrosothiols and nitric oxide, but not sodium nitroprusside, protect nigrostriatal dopamine neurons against iron-induced oxidative stress in vivo. Synapse 1996;23:58-60.
25. Muralikrishnan D, Mohanakumar KP. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine-induced neurotoxicity in mice. FASEB J 1998 ; 12:905-912.
26. Banerjee R, Saravanan KS, Thomas B, Sindhu KM, Mohanakumar KP. Evidence for hydroxyl radical scavenging action of nitric oxide donors in the protection against 1-methyl-4-phenylpyridinium-induced neurotoxicity in rats. Neurochem Res 2008;33:985-995.
27. Thomas T, Timmer M, Cesnulevicius K, Hitti E, Kotlyarov A, Gaestel M. MAPKAP kinase 2-defi ciency prevents neurons from cell death by reducing neuroInflammation-relevance in a mouse model of Parkinson ' s disease. J Neurochem 2008;105:2039-2052.
28. Madathil KS, Karuppagounder SS, Haobam R, Varghese M, Rajamma U, Mohanakumar KP. Nitric oxide synthase inhibitors protect against rotenone-induced, oxidative stress mediated parkinsonism in rats. Neurochem Int 2013;62:674-683.
29. Laranjinha J, Santos RM, Lourenco CF, Ledo A, Barbosa RM. Nitric oxide signaling in the brain: translation of dynamics into respiration control and neurovascular coupling. Ann N Y Acad Sci 2012;1259:10-18.
30. Underbakke ES, Iavarone AT, Chalmers MJ, Pascal BD, Novick S, Griffin PR, Marletta MA. Nitric oxide-induced conformational changes in soluble guanylate cyclase. Structure 2014;22:602-611.
31. Ju TC, Chen SD, Liu CC, Yang DI. Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotox-icity. Free Radic Biol Med 2005;38:938-949.
32. Iyer AK, Rojanasakul Y, Azad N. Nitrosothiol signaling and protein nitrosation in cell death. Nitric Oxide 2014;42C:9-18.
33. Halliwell B, Gutteridge J. Free radicals in biology and medicine. Oxford: Clarendon Press; 1999.
34. Girard P, Potier P. NO, thiols and disulfides. FEBS Lett 1993; 320:7-8.
35. Nakamura T, Wang L, Wong CC, Scott FL, Eckelman BP, Han X, et al. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Mol Cell 2010;39:184-195.
36. Ayton S, Lei P, Hare DJ, Duce JA, George JL, Adlard PA, et al. Parkinson's disease iron deposition caused by nitric oxide-induced loss of beta-amyloid precursor protein. J Neu-rosci 2015;35:3591-3597.
37. Han JY, Kang MJ, Kim KH, Han PL, Kim HS, Ha JY, Son JH. Nitric oxide induction of parkin translocation in PTEN-induced putative kinase 1 (PINK1) defi ciency: Functional role of neuronal nitric oxide synthase during mitophagy. J Biol Chem 2015;290:10325-10335.
38. Yin L, Xie Y, Yin S, Lv X, Zhang J, Gu Z, et al. The S-nitrosylation status of pcna localized in cytosol impacts the apoptotic pathway in a Parkinson ' s disease paradigm. PLoS One 2015;10:e0117546.
39. Bortolanza M , Cavalcanti-Kiwiatkoski R , Padovan-Neto FE , da-Silva CA, Mitkovski M, Raisman-Vozari R, Del-Bel E. Glial activation is associated with l-DOPA induced dyski-nesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease. Neurobiol Dis 2014;73C: 377-387.
40. Choi MS, Nakamura T, Cho SJ, Han X, Holland EA, Qu J, et al. Transnitrosylation from DJ-1 to PTEN attenuates neuronal cell death in parkinson ' s disease models. J Neurosci 2014;34:15123-15131.
41. Sunico CR, Nakamura T, Rockenstein E, Mante M, Adame A, Chan SF, et al. S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson ' s disease. Mol Neurodegener 2013;8:29.
42. Nunes C, Barbosa RM, Almeida L, Laranjinha J. Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis. Mol Cell Neurosci 2011 ; 48 : 94-103.
43. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. NeuroInflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008;28:7687-7698.
44. Fang J, Nakamura T, Cho DH, Gu Z, Lipton SA. S-nitrosyla-tion of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson ' s disease. Proc Natl Acad Sci U S A 2007;104:18742-18747.
45. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, et al. S-nitrosylated protein-disulphide isomerase links protein mis-folding to neurodegeneration. Nature 2006;441:513-517.
46. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson ' s disease. FASEB J 2005;19:533-542.
47. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, et al. S-nitrosylation of parkin regulates ubiquitina-tion and compromises parkin ' s protective function. Science 2004;304:1328-1331.
48. Bashkatova V, Alam M, Vanin A, Schmidt WJ. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp Neurol 2004;186:235-241.
49. Wu DC , Jackson-Lewis V , Vila M , Tieu K , Teismann P , Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrid-ine mouse model of Parkinson disease. J Neurosci 2002 ; 22:1763-1771.
50. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999;5:1403-1409.
51. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, et al. FcepsilonRII/CD23 is expressed in Parkinson ' s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999;19:3440-3447.
52. Smith TS, Swerdlow RH, Parker WD Jr, Bennett JP Jr. Reduction of MPP( + )-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994;5:2598-2600.
53. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996;2:1017-1021.
54. Canals S, Casarejos MJ, de Bernardo S, Rodriguez-Martin E, Mena MA. Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J Neurochem 2001; 79:1183-1195.
55. Bredt DS. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999;31: 577-596.
56. Peunova N, Enikolopov G. Nitric oxide triggers a switch to growth arrest during diff erentiation of neuronal cells. Nature 1995;375:68-73.
57. Kavya R , Saluja R , Singh S , Dikshit M. Nitric oxide synthase regulation and diversity: implications in Parkinson ' s disease. Nitric Oxide 2006;15:280-294.
58. Zhou L, Zhu DY. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009;20:223-230.
59. Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Trans-lational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A 2003;100:4843-4848.
60. Perez-Rodriguez R, Olivan AM, Roncero C, Moron-Oset J, Gonzalez MP, Oset-Gasque MJ. Glutamate triggers neurosecretion and apoptosis in bovine chromaffi n cells through a mechanism involving NO production by neuronal NO synthase activation. Free Radic Biol Med 2014;69:390-402.
61. Li LL, Ginet V, Liu X, Vergun O, Tuittila M, Mathieu M, et al. The nNOS-p38MAPK pathway is mediated by NOS1AP during neuronal death. J Neurosci 2013;33:8185-8201.
62. Bryan NS, Grisham MB. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med 2007;43:645-657.
63. Nishi A, Watanabe Y, Higashi H, Tanaka M, Nairn AC, Greengard P. Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades. Proc Natl Acad Sci U S A 2005 ; 102 : 1199-1204.
64. DiMatteo V, PierucciM, Benigno A, Orban G, Crescimanno G, Esposito E, Di Giovanni G. Electrophysiological and neurochemical characterization of 7-nitroindazole and molsidomine acute and sub-chronic administration effects in the dopaminergic nigrostrial system in rats. J Neural Transm Suppl 2009;73:173-182.
65. Sammut S, Dec A, Mitchell D, Linardakis J, Ortiguela M, West AR. Phasic dopaminergic transmission increases NO effl ux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neu-ropsychopharmacology 2006;31:493-505.
66. Sammut S, Bray KE, West AR. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psy-chopharmacology (Berl) 2007;191:793-803.
67. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkin-sonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
68. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984;311:464-467.
69. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jacobowitz DM, Kopin IJ. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, Guinea pig, and monkey. Psychopharmacol Bull 1984;20:548-553.
70. Donnan GA, Kaczmarczyk SJ, Solopotias T, Rowe P, Kalnins RM, Vajda FJ, Mendelsohn FA. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine in small animals. Clin Exp Neurol 1986 ; 22 : 155-164.
71. Mitra N, Mohanakumar KP, Ganguly DK. Resistance of golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-dine: relationship with low levels of regional monoamine oxidase B. J Neurochem 1994;62:1906-1912.
72. Heikkila RE, Sieber BA, Manzino L, Sonsalla PK. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 1989;10:171-183.
73. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP. Swim-test as a function of motor impairment in MPTP model of Parkinson ' s disease: a comparative study in two mouse strains. Behav Brain Res 2005;163:159-167.
74. Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, Mohanakumar KP. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkin-sonism. J Pineal Res 2013;55:304-312.
75. Pennathur S , Jackson-Lewis V , Przedborski S , Heinecke JW. Mass spectrometric quantifi cation of 3-nitrotyrosine, ortho-tyrosine, and o,o ′ -dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson ' s disease. J Biol Chem 1999 ; 274:34621-34628.
76. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, Hirsch EC. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72: 355-363.
77. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Defi -ciency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000;74:2213-2216.
78. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 1996;93:4565-4571.
79. Mackenzie GM , Jackson MJ , Jenner P , Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 1997;26:301-316.
80. Thomas B, Muralikrishnan D, Mohanakumar KP. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahy-dropyridine in mice. Brain Res 2000;852:221-224.
81. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970 ; 24 : 485-493.
82. Borah A, Mohanakumar KP. L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson ' s disease patients. Med Hypotheses 2012;79:271-273.
83. Borah A, Mohanakumar KP. L-DOPA-induced 6-hydroxy-dopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem Int 2010 ; 56 : 357-362.
84. Borah A, Mohanakumar KP. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism. Brain Res 2010; 1344: 192-199.
85. Senthilkumar KS, Saravanan KS, Chandra G, Sindhu KM, Jayakrishnan A, Mohanakumar KP. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Behav Brain Res 2007;184: 11-18.
86. Sindhu KM, Banerjee R, Senthilkumar KS, Saravanan KS, Raju BC, Rao JM, Mohanakumar KP. Rats with unilateral median forebrain bundle, but not striatal or nigral, lesions by the neurotoxins MPP+ or rotenone display diff erential sensitivity to amphetamine and apomorphine. Pharmacol Bio-chem Behav 2006;84:321-329.
87. Curtius HC, Wolfensberger M, Steinmann B, Redweik U, Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 1974;99:529-540.
88. Evans J, Cohen G. Catecholamine uptake inhibitors elevate 6-hydroxydopamine in brain after administration of 6-hydrox-ydopa. Eur J Pharmacol 1993;232:241-245.
89. Liao PC, Kuo YM, Chang YC, Lin C, Cherng CF, Yu L. Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine. J Neural Transm 2003;110:487-494.
90. Borah A, Mohanakumar KP. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 2009 ; 47:293-300.
91. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993;18:1175-1177.
92. Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, Day a S. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005;1063:180-186.
93. Riobo NA, Schopfer FJ, Boveris AD, Cadenas E, Poderoso JJ. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson ' s disease. Free Radic Biol Med 2002 ; 32:115-121.
94. Tuncel N, Korkmaz OT, Tekin N, Sener E, Akyuz F, Inal M. Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J Mol Neurosci 2012;46:51-57.
95. Barthwal MK , Srivastava N , Dikshit M. Role of nitric oxide in a progressive neurodegeneration model of Parkinson ' s disease in the rat. Redox Rep 2001;6:297-302.
96. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson ' s disease and other neurodegenerative diseases aff ecting the basal ganglia. Brain 1991 ; 114:1953-1975.
97. Mohanakumar KP, de Bartolomeis A, Wu RM, Yeh KJ, Sternberger LM, Peng SY, et al. Ferrous-citrate complex and nigral degeneration: evidence for free-radical formation and lipid peroxidation. Ann N Y Acad Sci 1994;738:392-399.
98. Sziraki I, Mohanakumar KP, Rauhala P, Kim HG, Yeh KJ, Chiueh CC. Manganese: a transition metal protects nigros-triatal neurons from oxidative stress in the iron-induced animal model of parkinsonism. Neuroscience 1998;85: 1101-1111.
99. Schipper HM, Vininsky R, Brull R, Small L, Brawer JR. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp Neurol 1998 ; 152 : 188-196.
100. Pezzella A, d'Ischia M, Napolitano A, Misuraca G, Prota G. Iron-mediated generation of the neurotoxin 6-hydroxy-dopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson ' s disease. J Med Chem 1997;40:2211-2216.
101. Mohanakumar KP, Thomas B, Sharma SM, Muralikrishnan D, Chowdhury R, Chiueh CC. Nitric oxide: an antioxidant and neuroprotector. Ann N Y Acad Sci 2002;962:389-401.
102. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson ' s disease. Nat Neurosci 2000;3:1301-1306.
103. Alam M, Schmidt WJ. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res 2002;136:317-324.
104. Fleming SM, Zhu C, Fernagut PO, Mehta A, DiCarlo CD, Seaman RL, Chesselet MF. Behavioral and immunohisto-chemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone. Exp Neurol 2004 ; 187:418-429.
105. Sindhu KM, Saravanan KS, Mohanakumar KP. Behavioral diff erences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res 2005;1051:25-34.
106. Tripathy D, Haobam R, Nair R, Mohanakumar KP. Engraft-ment of mouse embryonic stem cells diff erentiated by default leads to neuroprotection, behaviour revival and astrogliosis in parkinsonian rats. PLoS One 2013;8:e72501.
107. Saravanan KS, Sindhu KM, Mohanakumar KP. Acute intran-igral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson ' s disease. Brain Res 2005;1049:147-155.
108. Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemi-parkinsonian rat model. J Pineal Res 2007;42:247-253.
109. Chou AP, Li S, Fitzmaurice AG, Bronstein JM. Mechanisms of rotenone-induced proteasome inhibition. Neurotoxicology 2010;31:367-372.
110. Saravanan KS, Sindhu KM, Senthilkumar KS, Mohanakumar KP. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int 2006;49:28-40.
111. Madathil SK, Karuppagounder SS, Mohanakumar KP. Sodium salicylate protects against rotenone-induced parkin-sonism in rats. Synapse 2013;67:502-514.
112. Karuppagounder SS, Madathil KS, Pandey M, Haobam R, Rajamma U, Mohanakumar KP. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson ' s disease in rats. Neuroscience 2013;236:136-148.
113. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38:1285-1291.
114. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46: 598-605.
115. Castano A, Herrera AJ, Cano J, Machado A. Lipopolysac-charide intranigral injection induces infl ammatory reaction and damage in nigrostriatal dopaminergic system. J Neuro-chem 1998;70:1584-1592.
116. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional diff erence in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000;20:6309-6316.
117. Liu B, Jiang JW, Wilson BC, Du L, Yang SN, Wang JY, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intrani-gral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000;295:125-132.
118. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P. Involvement of inducible nitric oxide synthase in Inflammation-induced dopaminergic neurodegeneration. Neuroscience 2002;110:49-58.
119. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002;81:1285-1297.
120. Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopamin-ergic neurotoxicity of MPTP and infl ammogen lipopolysac-charide: relevance to the etiology of Parkinson ' s disease. FASEB J 2003;17:1957-1959.
121. Fahrig T , Gerlach I , Horvath E. A synt hetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson ' s disease and traumatic brain injury. Mol Pharmacol 2005;67:1544-1555.
122. Zhang W, Qin L, Wang T, Wei SJ, Gao HM, Liu J, et al. 3-Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neuro-toxicity. FASEB J 2005;19:395-397.
123. Zhang D, Hu X, Wei SJ, Liu J, Gao H, Qian L, et al. Squa-mosamide derivative FLZ protects dopaminergic neurons against Inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity. J Neuroinfl amma-tion 2008;5:21.
124. Cho Y, Son HJ, Kim EM, Choi JH, Kim ST, Ji IJ, et al. Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neu-rotox Res 2009;16:361-371.
125. Hancock DB, Martin ER, Vance JM, Scott WK. Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease. Neurogenetics 2008;9:249-262.
126. Rife T, Rasoul B, Pullen N, Mitchell D, Grathwol K, Kurth J. The effect of a promoter polymorphism on the transcription of nitric oxide synthase 1 and its relevance to Parkinson ' s disease. J Neurosci Res 2009;87:2319-2325.
127. Lo HS, Hogan EL, Soong BW. 5'-fl anking region polymorphism of the neuronal nitric oxide synthase gene with Parkinson's disease in Taiwan. J Neurol Sci 2002;194:11-13.
128. Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson ' s disease putamen. J Neural Transm Park Dis Dement Sect 1994;7:115-121.
129. Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, Lees AJ, et al. Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson ' s disease. Brain Res Mol Brain Res 1998;63:62-71.
130. Yin GN, Jeon H, Lee S, Lee HW, Cho JY, Suk K. Role of soluble CD14 in cerebrospinal fl uid as a regulator of glial functions. J Neurosci Res 2009;87:2578-2590.